GB9805561D0 - A combination of therapeutic agents - Google Patents

A combination of therapeutic agents

Info

Publication number
GB9805561D0
GB9805561D0 GBGB9805561.9A GB9805561A GB9805561D0 GB 9805561 D0 GB9805561 D0 GB 9805561D0 GB 9805561 A GB9805561 A GB 9805561A GB 9805561 D0 GB9805561 D0 GB 9805561D0
Authority
GB
United Kingdom
Prior art keywords
combination
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9805561.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB9805561.9A priority Critical patent/GB9805561D0/en
Publication of GB9805561D0 publication Critical patent/GB9805561D0/en
Priority to AU28464/99A priority patent/AU753077B2/en
Priority to CA002323618A priority patent/CA2323618A1/en
Priority to EP99909095A priority patent/EP1061952A2/en
Priority to PCT/GB1999/000778 priority patent/WO1999047131A2/en
Priority to JP2000536371A priority patent/JP2002506815A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9805561.9A 1998-03-16 1998-03-16 A combination of therapeutic agents Ceased GB9805561D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
AU28464/99A AU753077B2 (en) 1998-03-16 1999-03-16 Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
CA002323618A CA2323618A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
EP99909095A EP1061952A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
PCT/GB1999/000778 WO1999047131A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
JP2000536371A JP2002506815A (en) 1998-03-16 1999-03-16 Combination of GABAAα5 inverse agonist and acetylcholinesterase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Publications (1)

Publication Number Publication Date
GB9805561D0 true GB9805561D0 (en) 1998-05-13

Family

ID=10828631

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9805561.9A Ceased GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Country Status (6)

Country Link
EP (1) EP1061952A2 (en)
JP (1) JP2002506815A (en)
AU (1) AU753077B2 (en)
CA (1) CA2323618A1 (en)
GB (1) GB9805561D0 (en)
WO (1) WO1999047131A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
WO2001092257A1 (en) 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
WO2004058258A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20050267077A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2091948T3 (en) 2006-11-30 2012-07-23 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
CN102905532A (en) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
MX2012010470A (en) 2010-03-10 2012-10-09 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins Methods and compositions for treating schizophrenia
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN112843005B (en) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 Extended release pharmaceutical compositions of levetiracetam
KR101743960B1 (en) * 2015-07-06 2017-06-08 서울대학교산학협력단 G 19 Pharmaceutical composition for preventing treating or retarding Alzheimers disease or dementia comprising G protein-Coupled Receptor19 agonist as an active ingredient
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
JP2000515851A (en) * 1996-07-25 2000-11-28 メルク シヤープ エンド ドーム リミテツド Substituted triazolopyridazine derivatives as inverse agonists of the GABA lower Aα5 receptor subtype

Also Published As

Publication number Publication date
AU2846499A (en) 1999-10-11
EP1061952A2 (en) 2000-12-27
WO1999047131A3 (en) 1999-11-04
WO1999047131A2 (en) 1999-09-23
JP2002506815A (en) 2002-03-05
CA2323618A1 (en) 1999-09-23
AU753077B2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
GB9805561D0 (en) A combination of therapeutic agents
GB9820113D0 (en) Therapeutic agents
GB9708484D0 (en) Therapeutic agents
GB9708945D0 (en) Therapeutic agents
GB9816263D0 (en) Therapeutic agents
GB9806102D0 (en) Therapeutic agents
GB9704948D0 (en) Therapeutic agents
GB9702524D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9808663D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9801234D0 (en) Therapeutic agents
GB9813576D0 (en) Therapeutic agents
GB9813006D0 (en) Therapeutic agents
GB9801210D0 (en) Therapeutic agents
AP9901436A0 (en) Therapeutic agents
GB9801397D0 (en) Therapeutic agents
GB9702392D0 (en) Therapeutic agents
GB9805557D0 (en) A combination of therapeutic agents
GB9801202D0 (en) Therapeutic agents
GB9700555D0 (en) Therapeutic agents
GB9810092D0 (en) Therapeutic agents
GB9819484D0 (en) Therapeutic agents
GB9811879D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)